by Autoimmune polyglandular syndrome type 1 (APS1), also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), is a rare autoimmune disease characterized by chronic mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency. Some of the major advantages of APS1 treatment include management of chronic inflammation, prevention of organ damage, and improved quality of life. The growing prevalence of autoimmune diseases and increasing R&D investments are fueling the need for effective APS1 treatment options.
The global autoimmune polyglandular syndrome type 1 market is estimated to be valued at US$ 257 Mn in 2024 and is expected to exhibit a CAGR of 3.1% over the forecast period 2024 To 2031.
Key Takeaways
Key players operating in the global autoimmune polyglandular syndrome type 1 market are Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, F. Hoffmann-La Roche Ltd., Zydus Cadila, Lupin, Amneal Pharmaceuticals LLC., Cipla Inc., Aurobindo Pharma, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Allergan, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Abbott, and LEO Pharma A/S. Increasing public awareness and focus on early diagnosis of APS1 is driving the demand for treatment.
The growing prevalence of autoimmune diseases globally has increased the demand for effective treatment of rare conditions like APS1. According to the National Organization for Rare Disorders, it is estimated that there are between 1,000 to 2,000 known cases of Autoimmune Polyglandular Syndrome Type 1Market Size worldwide.
Geographically, North America dominates the global APS1 treatment market due to advanced healthcare infrastructure and high awareness. However, Asia Pacific is expected to exhibit the fastest growth over the forecast period due to improving access to diagnosis and treatment in the region.
Market Key Trends
Collaborations between key market players for drug development is a key trend in the global APS1 treatment market. In March 2022, Necker Hospital in Paris and University Children’s Hospital Zurich entered into a collaboration for improving understanding of APS1. This includes setting up a biobank and clinical registry to support future research. Such initiatives aim to accelerate development of novel APS1 treatment options.
Porter’s Analysis:
Threat of new entrants: Low barriers to entry in terms of capital requirements and technology. However, established brands, customer loyalty and regulatory requirements create advantages for existing players.
Bargaining power of buyers: Large buyers have significant bargaining power due to large order volumes. However, specialized nature of products limits impact on pricing.
Bargaining power of suppliers: Few manufacturers control key materials supply, giving them strong influence on prices. However, potential for forward integration mitigates impact.
Threat of new substitutes: Substitutes pose low threat currently due to differentiated nature of products and lack of viable alternatives. However, this may change with technology advancements.
Competitive rivalry: Intense competition among major multinational corporations. Companies compete based on innovation, pricing and brand reputation.
Geographical Regions:
North America currently holds the major share of the global market, supported by high incidence of autoimmune disorders and active research in the field. Key contributors include the United States and Canada.
The Asia Pacific region is expected to be the fastest growing market during the forecast period. This can be attributed to improving access to healthcare facilities, increasing medical tourism and rising disposable incomes in developing countries such as India and China.
